MGYR Q4 2025 Earnings EPS of 040 Reported Stock Unchanged MoonLake Immunotherapeutics MLTX Q1 2026 Earnings EPS Misses Estimates as ClinicalStage Biotech Advances Pipeline Investors Title Company Q4 2025 Earnings Strong Profitability Amid Flat Revenue Trends OC Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response MSEX Q1 2026 Earnings EPS Misses Estimates by 196 Stock Rises 07 AEON Q4 2025 Earnings WiderThanExpected Loss as Biotech Continues PreRevenue Phase